Skin cancer vaccine BLA submitted by June 30, 2027?

Intismeran autogene is clearly in the late-stage bucket, and that alone makes a filing by June 2027 plausible. Moderna and Merck have the financial capacity, regulatory experience, and commercial incentive to move quickly if the pivotal data are strong enough to justify a BLA, but this is still a personalized oncology product rather than a conventional biologic with a straightforward launch package. The market price near 88 percent suggests participants believe the regulatory path is nearly de-risked, yet the remaining gap between late-stage development and an actual submission is still large enough that I would not treat this as close to certain.

The main argument for a Yes outcome is timing: if the phase 3 program produces a clean efficacy readout in 2026 or very early 2027, the sponsors could prepare and submit a dossier before the deadline, and FDA acceptance could follow soon after. The fact that the market question allows either an announced submission or FDA acceptance also helps the Yes case, because public confirmation may come from the company or the agency even if there is some lag between filing and disclosure. In other words, if the clinical catalyst arrives on schedule, the remaining regulatory steps are manageable within the window.

The case against Yes is that individualized neoantigen vaccines are operationally difficult to scale and validate, which can slow CMC readiness even when the science looks good. The pivotal readout itself is also a major timing risk: if the primary endpoint matures later than expected, if the data are mixed, or if the sponsors want more follow-up before filing, the submission could easily slip beyond June 2027. Because approval by the deadline would also resolve the market Yes, the event is slightly helped by the possibility of an unusually fast review, but that path still looks less likely than a normal submission and does not fully offset the timing risk.